A Shot in the Arm? FDA Committee To Review Merck and Glaxo HPV Vaccines
This article was originally published in The Pink Sheet Daily
For Merck, the outcome may mean a long-awaited move to market Gardasil to males; for Glaxo, this may be its chance to sell Cervarix in the U.S.
You may also be interested in...
Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.
Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.